Jeffrey  Arcara net worth and biography

Jeffrey Arcara Biography and Net Worth

Jeffrey Arcara joined Corvus in 2024 as Chief Business Officer to lead the company’s corporate strategy, business development, portfolio strategy, and new product planning. With over 30 years of commercial expertise in the biopharmacuetical industry, Mr. Arcara has broad functional experience across a range of large and small biopharma companies. He previously served as senior vice president, head global marketing & portfolio and strategy for the specialty and biosimilars business at Teva Pharmaceuticals where he held commercial leadership roles of increasing responsibility across several different disease areas. Mr. Arcara holds an MBA from the UCLA Anderson School of Management and a B.A. in Finance and Marketing from University of Wisconsin-Madison.

What is Jeffrey Arcara's net worth?

The estimated net worth of Jeffrey Arcara is at least $36.96 thousand as of November 12th, 2026. Arcara owns 3,497 shares of Corvus Pharmaceuticals stock worth more than $36,963 as of November 16th. This net worth estimate does not reflect any other assets that Arcara may own. Learn More about Jeffrey Arcara's net worth.

How do I contact Jeffrey Arcara?

The corporate mailing address for Arcara and other Corvus Pharmaceuticals executives is 901 Gateway Blvd, Third Floor, South San Francisco, CA, 94080. Corvus Pharmaceuticals can also be reached via phone at (650) 900-4520 and via email at [email protected]. Learn More on Jeffrey Arcara's contact information.

Has Jeffrey Arcara been buying or selling shares of Corvus Pharmaceuticals?

During the last quarter, Jeffrey Arcara has bought $50,478.26 in shares of Corvus Pharmaceuticals stock. Most recently, on Friday, November 13th, Jeffrey Arcara bought 1,003 shares of Corvus Pharmaceuticals stock. The stock was acquired at an average cost of $10.54 per share, with a total value of $10,571.62. Following the completion of the transaction, the insider now directly owns 4,500 shares of the company's stock, valued at $47,430. Learn More on Jeffrey Arcara's trading history.

Who are Corvus Pharmaceuticals' active insiders?

Corvus Pharmaceuticals' insider roster includes Jeffrey Arcara (Insider), William Jones (SVP, Pharmaceutical Development), Richard Miller (CEO), David Moore (Director), and Peter Thompson (Director). Learn More on Corvus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Corvus Pharmaceuticals?

During the last year, Corvus Pharmaceuticals insiders bought shares 4 times. They purchased a total of 26,200 shares worth more than $300,679.26. The most recent insider tranaction occured on November, 13th when insider Jeffrey Arcara bought 1,003 shares worth more than $10,571.62. Insiders at Corvus Pharmaceuticals own 19.7% of the company. Learn More about insider trades at Corvus Pharmaceuticals.

Information on this page was last updated on 11/13/2026.

Jeffrey Arcara Insider Trading History at Corvus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2026Buy1,003$10.54$10,571.624,500View SEC Filing Icon  
11/12/2026Buy497$11.12$5,526.643,497View SEC Filing Icon  
11/11/2026Buy3,000$11.46$34,380.003,000View SEC Filing Icon  
See Full Table

Jeffrey Arcara Buying and Selling Activity at Corvus Pharmaceuticals

This chart shows Jeffrey Arcara's buying and selling at Corvus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corvus Pharmaceuticals Company Overview

Corvus Pharmaceuticals logo
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Read More

Today's Range

Now: $10.59
Low: $10.43
High: $11.05

50 Day Range

MA: $11.18
Low: $9.38
High: $14.39

2 Week Range

Now: $10.59
Low: $6.39
High: $26.95

Volume

397,924 shs

Average Volume

1,831,284 shs

Market Capitalization

$893.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57